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Abstract: Patients suffering from mild asthma are divided into intermittent or persistent classes 
based on frequency of symptoms and reliever medication usage. Although these terms are used 
as descriptors, it is important to recognize the approach of focusing on asthma control in manag-
ing asthma patients. Beta-agonists are considered first-line therapy for intermittent asthmatics. 
If frequent use of beta-agonists occurs more than twice a week, controller therapy should be 
considered. For persistent asthma, low-dose inhaled corticosteroids are recommended in addi-
tion to reliever medication. Compliance to regular therapy can pose problems for disease 
management, and while intermittent controller therapy regimens have been shown to be effec-
tive, it is imperative to stress the value of regular therapy especially if an exacerbation occurs. 
It is also important when such an approach is adopted that there is regular re-evaluations of 
asthma control. This is because regular anti-inflammatory therapy may become necessary if 
symptoms become more persistent. Other therapies are seldom needed. Antileukotrienes can 
be considered an option for mild asthma; however, studies have shown that they are not as 
effective as inhaled corticosteroids. Aside from therapy, patient education, which includes a 
written action plan, should be a component of the patient’s strategy for disease management.
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Introduction
Mild asthma patients make up by far the biggest number of asthma patients. In a recent 
study of the economic burden of asthma among a population-based cohort of over 
150,000 patients, 67.1% were mild, 25.5% were moderate, and 7.4% were classified 
as severe. The severe group was responsible for over 60% of the health care costs,1 
but interestingly there was a significant burden in a minority of patients who were 
deemed to be mild at baseline but subsequently became poorly controlled. Mild inter-
mittent asthma is defined as having symptoms less than once a week, and having forced 
expiratory volume in one second (FEV1) or peak expiratory flow (PEF) $80% predicted 
with ,20% variability. Mild persistent asthma differs in that symptoms frequency is 
greater than once per week but less than once per day, and variability in FEV1 or PEF 
is ,20%–30%.2
Patients are generally not troubled by nocturnal awakenings and have a reasonable 
level of daily activity, especially in intermittent asthmatics. The concept of current control 
and future risk is important with all levels of asthma control but especially in patients 
with mild asthma. Patients may be willing to accept mild symptoms and have poor 
adherence with preventive therapy, not recognizing that these treatments are designed 
not only to control current asthma but also reduce the future risk of asthma exacerbations. Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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Most notably in a retrospective study of asthma deaths in 
Australia, among children and adolescents, over one-third of 
asthma patients who died from an acute asthma attack had 
been categorized as having mild asthma by either their parents 
or primary care physicians.3 In this review we focus on the 
management of mild asthma and base our recommendations 
primarily on the results of systematic reviews of the literature. 
Where appropriate, key individual studies will be cited. The 
review will also primarily focus on adult asthma.
Mild intermittent asthma
Beta 2-agonists
Inhaled short-acting beta 2-agonists (SABAs) provide rapid 
relief by reducing airway narrowing and its associated   
symptoms (cough, chest tightness, wheezing) via relaxation 
of smooth muscle within the airway walls. SABA therapy 
works within 5 minutes and relieves asthma symptoms   
for 3–6 hours. However, SABAs do not control the inflam-
matory process associated with asthma. Current guidelines 
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recommend SABAs as the therapy of choice for mild inter-
mittent asthma (see Figure 1).2,4 SABA usage should be 
limited to an as-needed basis, at the lowest dosage and fre-
quency allowing for symptomatic relief.5 As-needed therapy 
is preferred to continuous therapy due to the infrequent nature 
of symptoms in intermittent mild asthma as well as the lack 
of benefit and potential risks from sustained therapy espe-
cially in the absence of concomitant anti-inflammatory 
therapy.6 Patients can also use the bronchodilator for symp-
tom relief and every 4–6 hours for up to 24 hours in the 
presence of a viral respiratory infection. Furthermore, with 
as-needed therapy, the frequency of SABA usage can be used 
as a measure of asthma control. Once symptom relief with 
rescue medication is required more than twice weekly there 
should be early consideration for the introduction of anti-
inflammatory therapy. A useful analogy for patients taking 
only reliever therapy is to the use of analgesia for a dental 
cavity: the pain is relieved but the cavity remains. Similarly, 
use of a symptom reliever as regular treatment has the poten-
tial to mask the inflammatory changes that are associated 
with even mild asthma.
inhaled corticosteroids
When reliever therapy is required more than twice weekly, 
anti-inflammatory therapy should be introduced. This recom-
mendation is primarily based on evidence indicating clinical 
benefit with no significant risk from the long-term use of 
inhaled corticosteroids (ICSs) for asthma treatment. ICSs are 
also recommended based on evidence that even in mild asthma 
there is a significant airway inflammatory component.7
In a recent study, 96 mild intermittent asthma patients 
were randomly allocated to either treatment with SABA 
monotherapy or in addition with low dose ICS (beclometha-
sone diproprionate 250 µg/day).8 After 6 months, the SABA 
and ICS therapy showed a statistically significant   improvement 
in FEV1 (3.58 L versus 3.66 L) as well as improvements in 
FVC, FEV1/FVC, and PEF. In comparison, SABA mono-
therapy showed a statistically significant decrease in all 
analyzed spirometric parameters. However, there was no 
statistically significant variation between monotherapy and 
ICS combined with as-needed SABA with respect to lung 
function measurements. Daily asthma symptom scores sig-
nificantly decreased (0.63 versus 0.30) with ICS and SABA 
therapy and were significantly increased (from 0.46 to 0.62) 
in patients taking a SABA only. Lastly, a significant reduc-
tion in rescue medication usage was associated with a com-
bination of ICS and as-needed SABA therapy, compared 
with a significant increase in rescue medication usage 
associated with SABA monotherapy. The authors concluded 
that the addition of ICS therapy with as-needed beta 2-agonist 
was effective in mild intermittent asthma. However, the 
authors noted limitations including the short duration of the 
study and the low number of study participants.
Mild persistent asthma
iCS therapy
ICSs are the most important therapy for asthma, including mild 
intermittent asthma, due to their ability to control airway inflam-
mation (see Table 1). The efficacy of ICS therapy includes 
reducing asthma symptoms, improving lung function, decreas-
ing the frequency and severity of exacerbations, as well as 
improving quality of life. These findings have been highlighted 
in numerous studies as well as Cochrane reviews.9–13 In a 2008 
Cochrane review, incorporating 86 studies with 16,160 partici-
pants, the safety and efficacy of fluticasone was assessed in 
comparison to placebo.11 Twenty-four studies included patients 
with mild asthma and 19 had patients with mild to moderate 
asthma. In patients suffering from mild to moderate asthma, 
who were not on oral steroid therapy, fluticasone was shown 
to improve symptom scores, FEV1, and morning PEF.
In one of the largest studies specifically focusing on mild 
persistent asthma, the inhaled steroid treatment as regular 
therapy in early asthma (START) trial, included approxi-
mately 7200 patients (5–66 years) who were randomly 
assigned to either 400 µg budesonide (or 200 µg for patients 
,11 years of age) or placebo to assess whether early ICS 
therapy reduces the risk of severe exacerbations over a 3-year 
period.13 A total of 198/3568 patients within the placebo arm 
and 117/3597 patients within the budesonide arm (hazard 
ratio 0.56; 95% confidence interval [CI]: 0.45–0.71; 
P , 0.0001) experienced at least one severe asthma 
exacerbation. Moreover, patients receiving budesonide pre-
sented with more symptom-free days, and they required fewer 
Table 1 estimated adult daily doses of inhaled glucocorticoids
Drug Low daily  
dose (µg)
Medium daily 
dose (µg)
High daily 
dose (µg)
Beclomethasone 
dipropionate
200–500 .500–1000 .1000–2000
Budesonide 200–400 .400–800 .800–1600
Ciclesonide 80–160 .160–320 .320–1280
Flunisolide 500–1000 .1000–2000 .2000
Fluticasone propionate 100–250 .250–500 .500–1000
Mometasone furoate 200–400 .400–800 .800–1200
Triamcinolone acetonide 400–1000 .1000–2000 .2000
Note: For the appropriate use of inhaled corticosteroid therapy in mild asthma see 
text. Copyright © 2009, european Respiratory Society. Adapted with permission 
from Bateman eD, Hurd SS, Barnes PJ, et al. Global strategy for asthma management 
and prevention: GiNA executive summary. Eur Respir J. 2008;31:143–178.2Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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courses of systemic corticosteroids compared with patients 
in the placebo arm. With respect to lung function, budesonide 
significantly increased pre- and post- bronchodilator FEV1 
from baseline after 1 year and 3 years compared with placebo. 
However, although the effect remained significant, the impact 
of budesonide on pre- and post- bronchodilator FEV1 
decreased over time and was small at 3 years. It was suggested 
to possibly be due to the fact that placebo participants were 
more likely to utilize additional therapy.
In 2008, data from the 2-year open-label treatment fol-
low-up study were published from the START trial.14 A total 
of 5146 participants (2604 budesonide group, 2542 placebo 
group) were treated with once daily budesonide as continu-
ation of therapy or as add-on therapy from the 3-year double-
blind phase alongside their usual asthma   medications. 
Across the 5-year study period, pre-bronchodilator 
percent predicted FEV1 increased on average by 3.24%, 
whereas post-bronchodilator percent predicted FEV1 
decreased on average by 2.22%, regardless of randomized 
treatment. However, there was a significant treatment dif-
ference in pre-  bronchodilator percent predicted FEV1 
(1.21%) and post-  bronchodilator percent predicted FEV1 
(0.85%) in favor of budesonide in adults (aged 18 years and 
older). Nevertheless, at the end of the 2-year open label 
follow up period, no significant differences were observed 
between the budesonide and placebo group in terms of pre- 
and post-bronchodilator percent predicted FEV1, which were 
observed during the 3-year double-blind phase, due to rapid 
catch-up in lung function in the reference group. In second-
ary   outcomes, patients who initially began with budesonide 
showed a significant decrease in risk for severe asthma-
related events, as well as a decrease in need for additional 
asthma medication compared with the reference group.
With regard to the safety of ICS therapy, it is important 
to be aware that local side effects such as oropharyngeal 
candidiasis, occasional cough, and dysphonia may occur. 
However, it is very unusual in the absence of high-dose ICS 
for systemic side effects such as easy bruising, adrenal sup-
pression, cataracts, glaucoma, and decreased bone mineral 
density to be present.5 To alleviate the burden of local side 
effects, spacer devices, mouth washing, and prodrugs such 
as ciclesonide can be used. Both male and female adult 
patients should consider daily calcium and vitamin D supple-
mentation specifically if they are at high risk for osteoporosis 
or already have osteopenia. As for systemic side effects in 
adult asthma patients, current evidence implies that at doses 
of #400 µg/day of budesonide or equivalent systemic 
adverse effects are not a relevant concern.15,16
Regular versus intermittent iCS
While current guidelines recommend the daily use of low-dose 
ICS therapy, compliance with regular ICS therapy in mild 
asthma is of great concern. The possibility of patients using 
their controller medication intermittently is high. In a recent 
double-blind trial including 225 adults (the Improving Asthma 
Control Trial [IMPACT]), the efficacy of intermittent short-
course ICS therapy either alone or in conjunction with daily 
ICS or leukotriene receptor antagonist therapy was analyzed.17 
Within the 1-year study period, variation in morning PEF did 
not significantly differ between groups. Furthermore, nonsig-
nificant differences between groups were identified in post- 
bronchodilator FEV1 or patients suffering from one or more 
exacerbations. Asthma quality of life scores did not vary 
significantly between groups.   However, daily in addition to 
intermittent ICS were significantly superior with respect to 
pre-bronchodilator FEV1, asthma control scores, number of 
symptom free days, median sputum eosinophils, and median 
exhaled nitric oxide.   Nevertheless, the authors concluded that 
it may be feasible to treat with intermittent ICS therapy 
together with an action plan for patients suffering from mild 
asthma. An important consideration in making a recommenda-
tion for these patients relates to the risk of exacerbations. In 
the event of an asthma exacerbation, the importance of sub-
sequent regular anti-  inflammatory therapy should be empha-
sized. The impact of asthma exacerbations on decline in FEV1 
has been   documented.18 In addition, if a patient elects not to 
take   regular anti-inflammatory therapy it is important to have 
intermittent reassessment of the patient’s level of asthma 
control including lung function. It is not unusual in clinical 
practice to see patients who report intermittent episodes of 
what are described as “wheezy bronchitis” but on closer 
questioning are in fact mild asthma exacerbations, and these 
patients invariably display a loss in lung function. An impor-
tant consideration with all asthma patients is the need to 
reassure them about the safety of ICSs. ICSs are safe in the 
doses usually required for most asthma patients but this is 
especially true in mild asthma where the dose of ICSs required 
to achieve asthma control is such that it will not be associated 
with any systemic risks.
Combination therapy
Although current guidelines recommend the addition of 
long-acting beta-2-agonists (LABA) to ICS when control 
with ICS therapy alone cannot be achieved,4,19 the introduc-
tion of LABAs without prior ICS therapy is still prevalent.20 
In a 2009 Cochrane review, 27 trials including 8050 partici-
pants with mild to moderate asthma (12 trials with a mean Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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baseline FEV1 $80% predicted) evaluated the efficacy of a 
LABA+ICS combination therapy compared to ICS therapy 
alone in steroid-naïve persistent asthma patients.21 When 
comparing LABA+ICS versus a similar dose of ICS, com-
bination therapy did not significantly lower the risk of exac-
erbations requiring oral steroids, or exacerbations requiring 
hospital admissions compared with ICS therapy alone. More-
over, no significant differences were identified in serious 
adverse events or study withdrawals. However, combination 
therapy did lead to significant improvement in FEV1 from 
baseline, reduction in rescue beta-2-agonist usage, and 
improved symptom control. When specifically analyzing 
patients with an FEV1 $80% predicted, similar results were 
found with nonsignificant differences in the number of 
patients with exacerbations requiring systemic steroids (rela-
tive risk [RR] 1.02; 95% CI: 0.67–1.56), number of patients 
with exacerbations requiring hospitalization (RR 0.21; 95% 
CI: 0.01–4.27), serious adverse events (RR 1.54; 95% CI: 
0.53–4.45), total withdrawals (RR 0.84; 95% CI: 0.60–1.17), 
number of patients withdrawing due to poor asthma control 
or exacerbation (RR 1.41; 95% CI: 0.45–4.42), and number 
of patients withdrawing due to adverse effects (RR 1.39; 
95% CI: 0.55–3.51). Similarly, there was a significant dif-
ference in FEV1 at endpoint (mean difference 1.75; 
95% CI: 0.20–3.29) and in morning PEF (mean difference 
15.32; 95% CI: 9.63–21.00) in favor of combination therapy 
  compared with ICS therapy alone.
When comparing LABA+ICS versus a higher dose of 
ICS therapy, combination therapy was associated with 
patients being more likely to require oral corticosteroids as 
well as study withdrawal. Similar results were found during 
subanalysis for patients with FEV1 .80% predicted. 
No   significant difference was identified between groups for 
risk for serious adverse events both overall and with suba-
nalysis for patients with FEV1 .80% predicted.   Ultimately, 
the authors found that combining ICS and LABA therapy 
did not significantly affect the risk of patients requiring oral 
corticosteroids or hospitalization in steroid-naïve patients 
suffering from mild to moderate asthma. Moreover, com-
bination therapy in comparison with increasing ICS dosage 
appears to be inferior in reducing the risk of exacerbations 
requiring oral corticosteroids and withdrawals.
In 2007, a 6-month double-blind randomized trial (the 
Beclomethasone and Salbutamol Treatment [BEST] Study) 
was undertaken to assess the effectiveness of as-needed 
single-inhaler beclomethasone and salbutamol (albuterol) 
versus as-needed salbutamol, daily ICS with as-needed 
salbutamol, or daily ICS/salbutamol with as-needed 
  salbutamol.22 A total of 455 patients were included in the 
study (122 as-needed combination therapy, 118 as-needed 
salbutamol therapy, 106 regular ICS therapy, 109 regular 
combination therapy). Significantly higher morning PEF 
values were observed in the as-needed combination therapy 
and regular ICS therapy groups compared with as-needed 
salbumatol, whereas no significant variation was detected 
between regular ICS therapy and as-needed combination 
therapy. When directly compared with as-needed salbutamol, 
regular ICS therapy showed significantly less rescue medica-
tion usage. Alternatively, as-needed combination therapy 
had significantly fewer nocturnal awakenings when compared 
with as-needed salbutamol therapy. The percentage of 
patients with at least one exacerbation was significantly lower 
in both regular ICS therapy (5.66%), and in as-needed com-
bination therapy (4.92%) compared with as-needed salbuta-
mol therapy (17.80%). The authors concluded that as-needed 
combination therapy has comparative effectiveness to regular 
ICS therapy in mild asthma.
In a further Cochrane review, including 27 studies (25 adult 
trials) with patients suffering from mild to moderate asthma, 
the effectiveness and safety of combination therapy of ICS 
and antileukotrienes was analyzed versus ICS monotherapy.23 
The addition of antileukotrienes to ICS therapy did not sig-
nificantly reduce the risk of exacerbations requiring systemic 
steroids (RR 0.64; 95% CI: 0.38–1.07) compared with ICS 
therapy alone. Furthermore, the addition of antileukotriene 
versus ICS therapy did not significantly impact change in FEV1 
(weighted mean difference [WMD] 0.06L; 95% CI: -0.01–
0.14), quality of life (WMD 0.08; 95% CI: -0.03–0.20), 
nocturnal awakenings (WMD -6.25; 95% CI: -12.72–0.23), 
or symptom score (-0.10; 95% CI: -0.24–0.03). Significant 
differences between groups were identified in change from 
baseline in morning PEF (WMD 7.65 L/min; 95% CI: 3.55–
11.75), rescue inhaler use (WMD -1; 95% CI: -0.5 to -2 
puffs/week), and eosinophil counts in favor of antileukotrienes 
with ICS therapy.   Concerning safety, the analysis of risk of 
overall withdrawals as well as overall adverse effects showed 
no significant difference between groups.
Antileukotrienes
While ICSs remain the cornerstone for the treatment of mild 
asthma, some patients have concerns about the perceived 
adverse effects of ICS therapy, and will elect not to take ICS 
even though these concerns are not valid.24–26 As an alterna-
tive, antileukotrienes can be used for mild asthma patients 
with key advantages including oral administration as well as 
a perceived lack of adverse effects.27 A 2003 Cochrane Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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review, which contained 27 trials of asthma patients with 
mild to moderate asthma, analyzed the efficacy and safety 
of antileukotriene agents in comparison with ICS therapy.28 
Eight trials specifically focused on mild asthma. Patients on 
an antileukotriene regimen were found to be 65% more likely 
to suffer an exacerbation requiring systemic steroids as well 
as a 160% increased risk of withdrawal due to poor asthma 
control when compared with patients on ICS. Improvements 
in lung function, symptom control, nocturnal awakenings, 
quality of life, symptom-free days and rescue medication 
usage were also found to significantly favor the utilization 
of ICS therapy.
As guidelines favor the minimum therapeutic dosage to 
maintain asthma control, a recent study analyzed the effect 
of reducing twice daily ICS therapy.29 Five hundred well-
controlled patients with mild persistent asthma on twice daily 
fluticasone were randomly assigned to: 1) continue current 
regimen, 2) receive fluticasone and salmeterol once daily, or 
3) montelukast once daily. Treatment failure occurred in 
approximately 30% of participants switched to montelukast 
in comparison with only 20% of patients who either   continued 
fluticasone therapy or switched to combination therapy. 
However, across all treatment arms similar percentages of 
symptom-free days were observed. Ultimately, the authors 
concluded that while antileukotrienes are an option for mild 
persistent asthma, ICS therapy is still superior at maintaining 
asthma control. These sentiments are echoed in current 
guidelines.3
immunotherapy
Allergen-specific immunotherapy is stated to be a limited 
component of disease management in adults with asthma.3 
Immunotherapy is indicated if asthma is triggered by expo-
sure to airborne allergens, with poor response to asthma 
therapy or environmental controls, if avoiding the triggers 
is unrealistic or impossible. It is not indicated if the asthma 
is not of the allergic type. Controversy about its usage stems 
from its effectiveness to improve health outcomes conflicting 
with potential life-threatening adverse effects such as fatal 
anaphylaxis, as well as its cost and inconvenience because 
it requires coming in for regularly scheduled injections.   
A 2010 Cochrane review, with 88 trials including a total of 
3792 participants (3459 having asthma) sought to assess the 
effectiveness of allergen-specific immunotherapy for 
asthma.30 The authors found a significant reduction in asthma 
symptom scores, medication requirements and allergen-
specific bronchial hyper-reactivity as well as a nonsignificant 
reduction in nonspecific bronchial hyper-reactivity. No 
consistent effect on lung function was identified. The review 
identified concerns about the inability to clearly identify 
concealment allocation following randomization in numerous 
trials, along with significant patient heterogeneity being 
present across groups. The authors concluded that this review 
provides substantiation that allergen specific immunotherapy 
is efficacious in reducing asthma medication usage and 
asthma symptoms. However, from this review little guidance 
is available on the benefit of allergen-specific immunotherapy 
in comparison with other medications used in the treatment 
of asthma.
In another systematic review comprising 25 studies and 
1706 patients, sublingual immunotherapy’s (SLIT’s) effec-
tiveness was observed to provide modest benefit in patients 
predominantly suffering from mild to moderate asthma.31 
An important clinical finding was that only mild adverse 
effects were observed, such as local pruritis, erythema, and 
edema, and no severe reactions were present. Consequently, 
SLIT may be considered as an alternative treatment to sub-
cutaneous immunotherapy.
Patient education
Regardless of disease severity, patient education should be an 
integral component of asthma management as   recommended 
in multiple guidelines.4,32 Key elements of education include 
basic information on the pathophysiology of asthma, a review 
of inhaler technique, as well as the need to adhere to treatment 
regimens. Moreover, it is important to address with open-
ended questions potential patient concerns such as perceived 
side effects related to treatment. It is also   important to develop 
and give to the patient a written action plan detailing the signs 
and symptoms suggestive that asthma is worsening, alongside 
the appropriate actions to take.
In 2002, a Cochrane review analyzed the impact of 
asthma self-management education programs alongside 
regular physician review on health outcomes.33 The review 
comprised 36 trials with approximately 6000   participants. 
The study showed that self-management education signifi-
cantly reduced hospitalizations and emergency room visits. 
Furthermore, days off work or school, nocturnal asthma, 
and quality-of-life estimates were also shown to signifi-
cantly improve. One concern that arose was the significant 
heterogeneity identified in unscheduled doctor visits, days 
off work, nocturnal symptoms, and quality-  of-life out-
comes, with possible causes being varying definitions 
between articles. In conclusion, the authors found that 
education improves health outcomes in asthmatic patients. 
Moreover, the effects of education programs can be Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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increased with the incorporation of self-monitoring, regular 
medical review, and written action plans.
To further explore the effect of asthma education, a 
companion review was published to address the effects of 
education on health outcomes at its most superficial level, 
the exchange of knowledge concerning the causes of 
asthma, and its treatments.34 Limited asthma education 
excludes attitude or behavior modification as well as any 
attempt to develop self-management skills. Twelve trials 
were included in the systematic review. Results showed 
that limited asthma education did not reduce hospitaliza-
tions, doctor visits, time lost from work or school, and 
medication usage; nor did it improve lung function. How-
ever, in two studies, perceived asthma symptoms were 
shown to improve. Overall, these results support the theory 
that knowledge transfer alone has a limited capacity to 
modify behavior. Therefore, this limits its ability to modify 
health outcomes.
Conclusion
Mild asthma is still a considerable concern given that it com-
prises the largest number of asthma patients and because of the 
economic burden it places on health care systems. ICSs are the 
primary therapeutic option for mild persistent asthma, as well 
as mild intermittent asthma if the use of reliever medication is 
required more than twice weekly. This is due to the inability of 
SABA to provide effective current control as well as to prevent 
future severe asthma exacerbations. It is important to emphasize 
that at the low doses used in mild asthma, the systemic adverse 
effects are not a cause for concern. Multiple alternative treatment 
  regimens have been assessed for mild disease. Intermittent ICS 
as well as antileukotrienes have both been considered; however, 
regular ICS therapy has been found to be more effective. The 
combination of ICSs and LABAs has been shown to be of no 
additional benefit to regular ICS therapy in patients with mild 
asthma. Alternative treatments such as chromoglycate, acupunc-
ture, and phytotherapy can be considered; however, there is a 
lack of evidence supporting their utilization. Lastly, due to 
limitations and modest efficacy, allergen-specific immuno-
therapy plays a small role in asthma disease management.
Whether a patient suffers from either intermittent or 
persistent disease, all patients should be provided with a 
structured asthma education program. Patients should also 
receive a written action plan as it is important to inform 
patients not only on their current asthma control, but also on 
their potential risks in the future. A more in-depth analysis 
of the recommendation provided can be found in the Global 
Initiative for Asthma guidelines.5
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